Radiation plus drug combo for untreated bulky follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of slow-growing lymphoma (follicular lymphoma) that has a tumor mass at least 7 cm in size.
- You have not received any prior treatment for your lymphoma.
- Your doctor has decided you need to start treatment now.
- You are between 18 and 75 years old.
- You are generally active and able to care for yourself (ECOG score 0-2).
- Your blood counts, kidney, and liver function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
This trial tests a combination of targeted therapy (zanubrutinib) with standard chemotherapy (G-CHOP) for people with untreated follicular lymphoma that is intermediate or high risk. The goal is to see if this combination can improve outcomes compared to standard care.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.